DBTECH

VIEW IN BROWSER | SUBSCRIBE TUE, AUG 20, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Vaccine makers have set their eyes on the next big thing: Developing combination shots targeting both Covid and the flu. As Covid vaccination rates in the U.S. dwindle , Pfizer, Moderna and Novavax, among other companies, hope that more convenient combo shots offering protection against two viruses rather than one will increase uptake among Americans. Some health experts have cast doubt on that belief, CNBC previously reported .  Still, combo jabs may also reduce the burden that respiratory viruses – which typically spread at the same time each year – put on pharmacists and the broader U.S. health-care system.  The race to develop those jabs is heating up, as all three companies test their respective vaccines in mid or late-stage trials.  But Pfizer and its German partner BioNTech faced

VIEW IN BROWSER | SUBSCRIBE WED, AUG 14, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Novo Nordisk and Eli Lilly have so far dominated the booming market for a class of weight loss and diabetes drugs.  But Eli Lilly may be starting to gain an edge over its Danish competitor in the two-horse race to capitalize on the soaring demand for those treatments, also known as GLP-1s.  That became clear last week after the pair reported their respective second-quarter earnings .  "Lilly is pulling ahead in the metabolic duopoly," BMO Capital Markets analyst Evan Seigerman said in a research note Thursday.  On Aug. 7, Novo Nordisk trimmed its full-year profit outlook after reporting that quarterly sales of its weight loss injection Wegovy came in well below Wall Street's expectations. The disappointing result came due to higher-than-expected price concessions to pharmacy ben